$400 million. Six employees. Founded in 2025. That’s the math on Anthropic’s acquisition of Coefficient Bio, a stealth AI drug discovery startup that barely existed before Anthropic wrote the check.
The deal, reported by The Information and confirmed by TechCrunch, is all stock. Coefficient’s three co-founders include Aris Theologis, who built an Nvidia AI partnership at Evozyne, and Nathan Frey, a former Biogen principal scientist who left as recently as September. The three co-founders’ combined background spans AI partnerships, principal-level drug discovery, and life sciences venture. At $400M for six employees, you’re paying roughly $66 million per head.
So what’s Anthropic actually buying? Not revenue. Not a product. They’re buying a team that knows how to plug AI into drug discovery pipelines, and they’re buying it fast. Anthropic already launched Claude for Life Sciences in October and Claude for Healthcare in January. This acquisition plugs a specific gap: biological research execution, not just model capability.
HHS banned Claude in March after President Donald Trump sought to blacklist the company from the federal government, and the FDA’s Elsa tool (built on Claude) may be caught in the crossfire. Anthropic is doubling down on biotech just as its federal health relationships are shakiest.
OpenAI is running the same play with ChatGPT Health and its enterprise healthcare suite. Both companies are racing to own the AI layer inside drug development. At $400M for a one-year-old startup, Anthropic just set the floor for what AI biotech talent costs.
The company hasn’t confirmed the deal publicly.
Diana Kowalski